10-Q · May 5, 2026
Embecta Corp. faced significant challenges in Q2 2026, reporting a revenue drop of 14.4% to $221.8 million and a net loss of $4.1 million compared to a profit of $23.5 million in the prior year. The company cited…
Earnings analysis · 10-Q
EMBC earnings analysis
Filed August 7, 2026 · Our reading of the company's report
The latest report
The provided 10-Q extract does not include the current-period income statement, balance sheet, cash flow statement, segment results, or MD&A, so revenue, margin, EPS, cash flow, and working-capital trends cannot be…
Read full summary
The provided 10-Q extract does not include the current-period income statement, balance sheet, cash flow statement, segment results, or MD&A, so revenue, margin, EPS, cash flow, and working-capital trends cannot be quantified from the available filing text. The most material development is the August 6, 2026 credit amendment, which extends $210 million of revolver capacity but reduces total commitments to $310 million and increases pricing on the extended tranche. No material changes to previously disclosed risk factors were reported.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Partial Extension of Revolving Debt
The company extended $210 million of revolving commitments to December 30, 2028, improving the maturity profile for that tranche, while $100 million remains due March 31, 2027.
-
Share Repurchases Initiated
Embecta initiated a three-year $100.0 million stock repurchase plan and repurchased 2,684,582 shares during the quarter, including 1,356,644 shares in June at an average price of $3.23.
-
Effective Disclosure Controls
Management concluded that disclosure controls were effective as of June 30, 2026, and reported no material changes to internal control over financial reporting during the three months ended June 30, 2026.
What to watch
-
Higher-Cost and Reduced Revolver Capacity
Aggregate revolving credit commitments were reduced from $500 million to $310 million, while the extended tranche carries Term SOFR plus 3.50%, versus Term SOFR plus 3.00% for the non-extended tranche.
-
More Restrictive Financial Covenants
The amended credit agreement imposes a maximum Consolidated First Lien Net Leverage Ratio stepping from 4.75 to 1.00 through June 30, 2027 to 3.75 to 1.00 on and after April 1, 2028, plus a minimum interest coverage ratio rising from 2.50 to 1.00 through September 30, 2027 to 3.00 to 1.00 on and after January 1, 2028.
-
Interest and Liquidity Sensitivity
Based on borrowings at June 30, 2026, a 100-basis-point interest-rate change would affect annualized interest expense by $7.7 million; the amended agreement also requires monthly liquidity forecasts and account-balance reports until the extended commitments mature.
Management's outlook
No quantitative revenue or EPS outlook is included in the provided 10-Q extract; outlook may be addressed separately in the earnings release or call.
Earlier filings 4
10-Q · February 5, 2026
Embecta posted essentially flat revenue of $261.2 million for the three months ended December 31, 2025, while operating income rose to $83.3 million and GAAP net income was $44.1 million (diluted EPS $0.74). Cash from…
10-K · November 25, 2025
Embecta presents itself as a global diabetes device leader with products used by more than 30 million people in over 100 countries and a sizeable IP portfolio (about 655 patents and ~45 pending as of September 30,…
10-Q · August 8, 2025
Embecta reported a stronger quarter: revenues rose to $295.5 million (Q ended June 30, 2025) up from $272.5 million a year earlier and operating income increased to $94.0 million from $55.9 million. The company…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.